Cases & Deals

Galenica acquires Relypsa for $1.53 billion

Clients Galenica AG

Jones Day advised Galenica AG, a diversified group of companies active throughout the health care market, in its acquisition of Relypsa, Inc., a biopharmaceutical company focused on the discovery, development, and commercialization of polymeric medicines, pursuant to a tender offer in which Galenica paid $32 per share, or a total of $1.53 billion.

In addition to M&A representation, Jones Day provided antitrust, employee benefits, and tax advice regarding this transaction.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.